A detailed history of Nilsine Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Nilsine Partners, LLC holds 3,202 shares of VRTX stock, worth $1.49 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
3,202
Previous 3,450 7.19%
Holding current value
$1.49 Million
Previous $1.62 Billion 7.91%
% of portfolio
0.19%
Previous 0.22%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$460.0 - $505.78 $114,080 - $125,433
-248 Reduced 7.19%
3,202 $1.49 Billion
Q2 2024

Jul 31, 2024

SELL
$392.81 - $485.53 $12,177 - $15,051
-31 Reduced 0.89%
3,450 $1.62 Billion
Q1 2024

Apr 22, 2024

SELL
$407.69 - $446.08 $28,945 - $31,671
-71 Reduced 2.0%
3,481 $1.46 Billion
Q4 2023

Jan 24, 2024

SELL
$343.0 - $410.68 $603,680 - $722,796
-1,760 Reduced 33.13%
3,552 $1.45 Billion
Q3 2023

Nov 01, 2023

BUY
$338.18 - $362.46 $369,630 - $396,168
1,093 Added 25.91%
5,312 $1.85 Billion
Q2 2023

Jul 21, 2023

BUY
$314.42 - $351.91 $12,262 - $13,724
39 Added 0.93%
4,219 $1.48 Billion
Q1 2023

May 10, 2023

BUY
$283.23 - $323.1 $1.18 Million - $1.35 Million
4,180 New
4,180 $1.32 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nilsine Partners, LLC Portfolio

Follow Nilsine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nilsine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nilsine Partners, LLC with notifications on news.